Health Canada MDEL Modernization Phase 2: 2026 Changes for Importers and Distributors

FDA AI Medical Device Draft Guidance 2026: Lifecycle Management and Submission Requirements

The FDA's June 6, 2026 draft guidance introduces significant new requirements for AI-enabled medical devices, focusing on total product lifecycle management. This episode breaks down the key changes, including stricter rules for algorithm transparency, data provenance, AI-specific risk management, and real-world performance monitoring. We discuss who is affected, the critical August 5, 2026 deadline for public comment, and practical steps manufacturers should take now to prepare, such as conducting a gap analysis and updating their QMS. Key Questions: - What are the key changes in the FDA's new draft guidance for AI-enabled medical devices? - How does the guidance redefine requirements for algorithm transparency and data provenance? - What new AI-specific risk management activities must manufacturers incorporate? - What are the expectations for real-world performance monitoring of AI models? - Who is most affected by this new draft guidance? - What is the deadline for submitting public comments to the FDA? - How should regulatory teams conduct a gap analysis against these new requirements? - What practical steps can manufacturers take now to prepare for the final guidance? Sources: - https://www.youtube.com/watch?v=example_video_id_for_pure_global_podcast - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissions How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex requirements, like the FDA's new AI guidance. Our experts develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets. We help you conduct gap analyses, update your QMS, and ensure your AI device meets evolving standards for transparency and lifecycle management, accelerating your path to market. For support with your global regulatory needs, visit us at https://pureglobal.com, email info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Health Canada MDEL Modernization Phase 2: 2026 Changes for Importers and Distributors

Health Canada has finalized Phase 2 of its Medical Device Establishment Licence (MDEL) modernization, with new rules taking effect on December 14, 2026. This episode breaks down the three most significant changes impacting importers, distributors, and Class I manufacturers. We explore the new exemption for certain foreign distributors, the now-mandatory requirement for all MDEL holders to maintain supplier lists, and the shift from attestation to an explicit requirement for documented procedures covering recalls, complaints, and distribution. Learn the practical steps your organization must take to prepare for the 2026 compliance deadline. Key Questions: - What are the key changes in Health Canada's MDEL modernization Phase 2? - When do the new MDEL rules come into force? - Are foreign distributors of Class I devices still required to hold an MDEL? - What new documentation is required for all MDEL holders? - How does the new rule change the requirement for documented procedures? - Who is most affected by these amendments to the Medical Devices Regulations? - What are the mandatory procedures that must be documented under the new framework? - What practical steps should my company take to prepare for the December 14, 2026 deadline? Sources: - https://www.dicentra.com/blog/health-canada-finalizes-phase-2-mdel-modernization - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We can help you navigate Health Canada's new MDEL requirements by developing efficient regulatory strategies, compiling technical documentation with advanced AI, and ensuring your quality systems meet the new explicit requirements for documented procedures. Our local experts in Canada provide real-time, in-country support to ensure a smooth transition and ongoing compliance. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and global device database at https://pureglobal.ai to accelerate your market access.

Australia TGA Classification Rule 5.5: Reclassification Changes for Medical Devices

Australia's TGA has amended medical device classification rule 5.5, effective July 1, 2024. The change removes materials of microbial and recombinant origin from the scope of the rule, which previously mandated a Class III classification. This will lead to the down-classification of certain devices, such as some dermal fillers or surgical meshes, likely to Class IIb. Sponsors of existing devices on the ARTG must submit a reclassification application before the critical deadline of July 1, 2026, to continue supplying their products in Australia. Key Questions: - What specific changes did the TGA make to classification rule 5.5 on June 14, 2024? - How does this amendment affect medical devices containing materials of microbial or recombinant origin? - What is the new classification for devices that were previously Class III under this rule? - What is the critical deadline for sponsors of existing devices to apply for reclassification? - What happens if a sponsor misses the July 1, 2026 deadline? - Which types of medical devices are most likely to be impacted by this change? - What immediate steps should regulatory teams take to review their product portfolio? - How should manufacturers prepare their technical documentation for a reclassification submission to the TGA? Sources: - https://www.tga.gov.au/news/media-releases/medical-device-regulation-changes - https://regdesk.co/tga-notice-on-medical-device-regulations-change/ - https://www.tga.gov.au/resources/publication/regulatory-changes-medical-devices-containing-medicinal-substances-or-materials-animal-microbial-or-recombinant-origin How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We can help you navigate the TGA's reclassification requirements by developing a clear regulatory strategy, efficiently compiling your technical dossier using advanced AI, and managing your submission to ensure you meet the 2026 deadline. Our local experts in Australia provide in-country support, ensuring your transition is seamless and compliant. To learn how we can accelerate your market access, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Switzerland's Swissdamed: Mandatory Device and IVD Registration by July 2026

Switzerland's swissdamed database becomes mandatory on July 1, 2026, for all medical devices and IVDs. This episode details the key deadlines, including the transition period until December 31, 2026, for existing devices, the scope of registration for all device classes, and the new annual fee structure based on UDI-DI counts. We provide practical steps for manufacturers to ensure compliance and maintain market access. Key Questions: - What is swissdamed and why is registration becoming mandatory? - What is the hard deadline for registering new medical devices in Switzerland? - Is there a grace period for devices already on the Swiss market? - Who is responsible for completing the swissdamed registration? - How will the new annual fees be calculated? - What data is required for a successful swissdamed submission? - How does swissdamed relate to the EU's EUDAMED database? - What are the immediate actions our regulatory team should take now? - How should we budget for these new Swiss compliance costs? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFj9gp0vO4-6LvYlKcwb2YLx5oYsv4udU7wWV5RGMQijyeuyyGacP979aRCUNg8bssHZSs6vd1NfYkaFUvspjkAqNBlqg2xyuyPnILyVWhYaDSE5C2b4HwR_lcyEfqpQrmzPPRX7T3l9VRZySTeEPClPEmFWIK-HkbhLrriOOt8DTBPfHmlAKtxbUsBluS5QQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpyNws7TRfcaaytmOBTsjujC-25m_XDthiKPR_Qod5ih2zZAV5LbnTzLX5F4lZ0i1gqSQ-GzaPhoSQOgk2h-TntvCwcGk2x1gOjPrSmDVV8HIy6jjhTlfQll2FCd2PCIzMX2JTFVg5uXWqa4IPu6XsD7-fSzBVQ7nfZftBkNhtA0Gpv8VfzHjpuMLQrPfVQtprTFU= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5I2yE-gMvSGEiPlzmItcVirtLhjd-t6612Xz6CwdxpHyrCZSnannSPtxDN4ikIur8Z3qSKphYrAxRBl8rHkM9Qads2CixbbJ7Hg6zeOBRSeG94Xk2_AE2oagFEZ9h7vxF2uCdJqXCpdgUrVcNcgETx-ibRrZWya8s5ihjAAns28UYW0KYZ1RvaF7OzB1IQroyTy23zG_vOdFZ0k6q8xjkY2d-LnYEBQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE98pavdxGcQG6Ak49uInD79TeOqkrV1lDWdk2pbr9yW3wQWVUeK1KbUZIU_6sgW51FJgxlRs9DnghJktdCdCQvztBik7qkz3haJXi1k7zrk1PoCMVDguL1UCHNRlLdI6ltH8Wk2nkC0e44i5PSGkUHJe6GvlNOAJ3rQanyVQPYLkZvYmAxOgw= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGBHa2TzL0KLOkrmDyEjM0qYQ0XjFMAJaW2lmhERdq7JvbdDcu7yEw58vSZXYX4VvMXGYwhKvJ6XiXpoH8RovfI3o1vQOIrqeAO5E8E2kHpppZ98UgEfap6DdVQPFtcbcGH3wdyieJtbQCQMVI2NZfthHxapjBUY8ezbPa88lcoA5biINZOI9E32K_2TUW2bNpweSknDW5kLJrS How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, ensuring you can navigate complex changes like the mandatory swissdamed registration. We act as your Swiss Authorized Representative (CH-REP), manage the entire registration process, and develop strategies to minimize costs and ensure uninterrupted market access. Our AI-powered tools and expert local teams help you efficiently compile technical dossiers and monitor regulatory changes, so you can focus on innovation. For expert support on your path to global compliance, visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

UK MHRA International Reliance: Navigating the Draft 2026 Medical Device Regulations

This episode details the UK MHRA's draft Medical Devices (Amendment) Regulations 2026, focusing on the proposed International Reliance pathway. We explore how this new framework aims to streamline market access in Great Britain for devices already approved by regulators in the US, Canada, or Australia. We cover the significance of the stakeholder survey deadline of June 19, 2026, the anticipated entry into force in June 2027, and the practical steps manufacturers should take now to prepare for this major regulatory shift. Key Questions: - What is the UK MHRA's proposed International Reliance pathway? - Which international approvals will be recognized for faster Great Britain market access? - What was the significance of the June 19, 2026, stakeholder survey deadline? - When are the new Medical Devices (Amendment) Regulations 2026 expected to come into force? - How does this proposal change the post-Brexit regulatory landscape for medical devices in the UK? - What types of devices will be eligible for this new pathway? - What practical steps should regulatory teams take now to prepare for these changes? - How will this impact manufacturers who only have a CE mark? - What documentation might be required even under the reliance framework? Sources: - https://www.pinsentmasons.com/out-law/analysis/update-to-the-medical-devices-regulatory-regime-key-proposals-and-implications - https://www.dacbeachcroft.com/en/gb/articles/2026/june/mhra-publishes-draft-regulations-for-medical-device-reform/ - https://www.arnoldporter.com/en/perspectives/publications/2026/05/mhra-publishes-draft-amendment-to-the-uk-medical-devices-regulations - https://www.jdsupra.com/legalnews/recent-eu-and-uk-medical-devices-8991557/ - https://www.gs1uk.org/news-research/news/mhra-draft-reforms-for-medical-device-regulation-in-great-britain How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex regulatory shifts like the UK's new International Reliance pathway. Our experts develop efficient market access strategies, act as your local UK Responsible Person, and use advanced AI to compile and manage technical submissions, ensuring you are prepared for the June 2027 changes. We help you leverage existing approvals to accelerate entry into new markets while maintaining compliance. For support with your global regulatory strategy, contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.